Aarti Pharmalabs Limited has disclosed receiving a penalty of Rs 2.60 lakhs from the CGST and Central Excise authority, as mandated under Regulation 30 of SEBI Listing Regulations. The penalty was imposed by the Office of the Assistant Commissioner, CGST and Central Excise, Circle-VIII, Vapi, Gujarat, with the order received on February 3rd, 2026.

Penalty Details and Regulatory Action

The penalty has been imposed under Section 74 of the CGST Act, 2017, forming part of a larger alleged demand totaling Rs 31,15,608. This demand amount is inclusive of tax, interest, and penalty components related to GST compliance issues.

Nature of Alleged Violations

The regulatory action stems from alleged discrepancies in the company's GST compliance for financial years 2022-23 and 2023-24. The specific violations identified by the authority include:

• Alleged excess availment of Input Tax Credit
• Incorrect declaration of tax liability
• Discrepancies in data submitted under various GST returns including GSTR-3B, GSTR-1, GSTR-9, and GSTR-2A
• Issues identified in other related records

Financial and Operational Impact

The company has assessed that this penalty will not have any material impact on its financial position, operations, or other business activities. This disclosure suggests that the penalty amount, while significant in absolute terms, is manageable within the company's current financial framework.

Compliance and Next Steps

Aarti Pharmalabs Limited has committed to submitting necessary information and documents to the relevant authority as part of the compliance process. The company has fulfilled its disclosure obligations by informing both BSE and NSE about this development, and has also uploaded the information on its official website at www.aartipharmalabs.com .

The disclosure was signed by Jeevan Mondkar, Company Secretary and Legal Head, ensuring proper corporate governance protocols were followed in communicating this regulatory development to stakeholders.

Aarti Pharmalabs Limited has officially announced its quarterly earnings conference call to discuss Q3FY26 financial results. The pharmaceutical company issued a formal intimation to stock exchanges on February 02, 2026, under Regulation 30 of the SEBI (LODR) Regulations 2015.

Conference Call Details

The earnings conference call has been scheduled as a group meeting for investors and analysts. The company will host the session to provide comprehensive insights into its third quarter performance for fiscal year 2026.

Management Participation

The earnings call will feature key leadership members who will present the quarterly results and address participant queries. The company has confirmed participation from its senior management team.

Access Information

The company has provided multiple access options for participants, including domestic dial-in numbers and international toll-free lines. Participants can pre-register to avoid waiting queues through the DiamondPass registration link.

Domestic Access Numbers

International Toll-Free Access

Regulatory Compliance

The earnings call announcement was made in compliance with regulatory requirements, with the company informing both BSE Limited (Scrip Code: 543748) and National Stock Exchange of India Limited (Symbol: AARTIPHARM). The intimation was signed by Company Secretary and Legal Head Jeevan Mondkar on February 02, 2026.

For additional information regarding the conference call, participants can contact Candice Pareira, AVP Research at Dolat Capital Market Pvt. Ltd., or Zain Gulam Hussain, Research Associate at the same firm.